Rosowsky A, Forsch R A, Bader H, Freisheim J H
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115.
J Med Chem. 1991 Apr;34(4):1447-54. doi: 10.1021/jm00108a032.
The 5-deaza and 5,8-dideaza analogues of N alpha-pteroyl-L-ornithine (Pter-Orn), the 5-deaza, 8-deaza, and 5,8-dideaza analogues of N alpha-(4-amino-4-deoxypteroyl)-L-ornithine (APA-Orn), and the N delta-carboxymethyl derivative of N alpha-(4-amino-4-deoxy-N10-methylpteroyl)-L-ornithine (mAPA-Orn) were synthesized and tested as inhibitors of dihydrofolate reductase (DHFR) and as inhibitors of tumor cell growth in culture. Reductive amination of 2-acetamido-6-formylpyrido[2,3-d]pyrimidine-4(3H)-one with methyl N alpha-(4-aminobenzoyl)-N delta-(benzyloxycarbonyl)-L-ornithinate followed by removal of the blocking groups afforded the 5-deaza analogue of Pter-Orn, whereas N-alkylation of methyl N alpha-(4-aminobenzoyl)-N delta-(benzyloxycarbonyl)-L-ornithinate with 2-amino-6-(bromomethyl)quinazolin-4(3H)-one and deprotection gave the corresponding 5,8-dideaza analogue. Reductive coupling of 2,4-diaminopyrido[2,3-d]pyrimidine-6-carbonitrile and 4-aminobenzoic acid followed by reaction with 95-97% formic acid yielded 4-amino-4-deoxy-5-deaza-N10-formylpteroic acid, which on condensation with methyl N delta-(benzyloxycarbonyl)-L-ornithinate and deprotection gave the 5-deaza analogue of APA-Orn. A similar sequence starting from 2,4-diamino-quinazoline-6-carbonitrile led to the corresponding 5,8-dideaza compound, whereas treatment of 2,4-diamino-pyrido[3,2-d]pyrimidine-6-methanol with phosphorus tribromide followed by condensation with methyl N alpha-(4-aminobenzoyl)-N delta-(benzyloxycarbonyl)-L-ornithinate and deprotection afforded the 8-deaza analogue. For the preparation of the N delta-carboxymethyl derivative of mAPA-Orn, N alpha-(benzyloxycarbonyl)-L-ornithine was subjected to N delta-monoalkylation with glyoxylic acid and sodium cyanoborohydride, followed by N delta-acylation with ethyl trifluoroacetate, N alpha-deprotection by hydrogenolysis, condensation with 4-amino-4-deoxy-N10-methylpteroic acid, and N delta-deprotection by gentle treatment with ammonia. The 2,4-diamino derivatives all inhibited the growth of tumor cells in culture, with IC50 values of 0.2-2 microM, and inhibited purified DHFR with IC50 values of 0.02-0.08 microM. Deletion of ring nitrogens and N delta-carboxymethylation both increased potency in the cell growth assay; however, the ornithine derivatives were less potent than aminopterin or methotrexate.
合成了Nα-蝶酰-L-鸟氨酸(Pter-Orn)的5-脱氮和5,8-双脱氮类似物、Nα-(4-氨基-4-脱氧蝶酰)-L-鸟氨酸(APA-Orn)的5-脱氮、8-脱氮和5,8-双脱氮类似物以及Nα-(4-氨基-4-脱氧-N10-甲基蝶酰)-L-鸟氨酸(mAPA-Orn)的Nδ-羧甲基衍生物,并测试了它们作为二氢叶酸还原酶(DHFR)抑制剂和培养中肿瘤细胞生长抑制剂的活性。2-乙酰氨基-6-甲酰基吡啶并[2,3-d]嘧啶-4(3H)-酮与Nα-(4-氨基苯甲酰基)-Nδ-(苄氧羰基)-L-鸟氨酸甲酯进行还原胺化反应,随后除去保护基,得到Pter-Orn的5-脱氮类似物;而Nα-(4-氨基苯甲酰基)-Nδ-(苄氧羰基)-L-鸟氨酸甲酯与2-氨基-6-(溴甲基)喹唑啉-4(3H)-酮进行N-烷基化反应并脱保护,得到相应的5,8-双脱氮类似物。2,4-二氨基吡啶并[2,3-d]嘧啶-6-腈与4-氨基苯甲酸进行还原偶联反应,随后与95-97%的甲酸反应,得到4-氨基-4-脱氧-5-脱氮-N10-甲酰蝶酸,其与Nδ-(苄氧羰基)-L-鸟氨酸甲酯缩合并脱保护,得到APA-Orn的5-脱氮类似物。从2,4-二氨基喹唑啉-6-腈开始的类似反应序列得到相应的5,8-双脱氮化合物;而2,4-二氨基吡啶并[3,2-d]嘧啶-6-甲醇用三溴化磷处理,随后与Nα-(4-氨基苯甲酰基)-Nδ-(苄氧羰基)-L-鸟氨酸甲酯缩合并脱保护,得到8-脱氮类似物。为了制备mAPA-Orn的Nδ-羧甲基衍生物,Nα-(苄氧羰基)-L-鸟氨酸用乙醛酸和氰基硼氢化钠进行Nδ-单烷基化反应,随后用三氟乙酸乙酯进行Nδ-酰化反应,通过氢解进行Nα-脱保护,与4-氨基-4-脱氧-N10-甲基蝶酸缩合,并通过用氨温和处理进行Nδ-脱保护。所有的2,4-二氨基衍生物在培养中均能抑制肿瘤细胞的生长,IC50值为0.2-2微摩尔,并且能抑制纯化的DHFR,IC50值为{0.02-0.08微摩尔}。环氮的缺失和Nδ-羧甲基化在细胞生长试验中均提高了活性;然而,鸟氨酸衍生物的活性低于氨甲蝶呤或甲氨蝶呤。